Roche expects to report unchanged, or slightly increased, sales for 2022 as demand for new products offsets sales declines for Herceptin and other legacy medicines which are now competing against cheaper biosimilar products. The Swiss multinational said it expects to increase its dividend for 2022. As is customary, it did not report operating or net profit figures for the third quarter and the nine-month period.
